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Objectives: To assess the cost-effectiveness ratio of rifampin for 4 months and isoniazid for 6
months in contacts with latent tuberculosis infection.
Methods: The cost was the sum of the cost of treatment with isoniazid for 6 months or with
rifampin for 4 months of all contacts plus the cost of treatment of cases of tuberculosis not
avoided. The effectiveness was the number of cases of tuberculosis avoided with isoniazid
for 6 months or with rifampin for 4 months. When the cost with one schedule was found to
be cheaper than the other and a greater number of tuberculosis cases were avoided, this sche-
dule was considered dominant. The efficacy adopted was 90% for rifampin for 4 months and
69% for isoniazid for 6 months. A sensitivity analysis was made for efficacies of rifampin for
4 months of 80%, 69%, 60% and 50%.
Results: Of the 1002 patients studied, 863 were treated with isoniazid for 6 months and 139
with rifampin for 4 months The cost-effectiveness ratio with isoniazid for 6 month was V
19759.48/avoided case of tuberculosis and V 8736.86/avoided case of tuberculosis withgila`ncia Epidemiolo`gica Valle`s Occidental i Valle`s Oriental Programa de Tuberculosi, Rambla d’E´gara
ain. Tel.: þ34 937842661; fax: þ34 936932539.
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4RIF, 6INH, cost-effectiveness 769rifampin for 4 months. Rifampin for 4 months was dominant. In the sensitivity analysis, rifam-
pin for 4 months was dominant for efficacies from 60%.
Conclusions: Rifampin for 4 months was more cost-effective than isoniazid for 6 months.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
The priority in the control of tuberculosis (TB) is curing the
patient, but preventing the development of the disease is
also important.1 It has been suggested that a simultaneous
attack on both active TB and latent infection would mark-
edly increase the chance of eliminating the disease during
the twenty-first century.2
The risk of any patient with latent tuberculosis infection
(LTBI) of developing tuberculosis may be reduced by
treatment.1,3,4 This reduction may be achieved using iso-
niazid (H) in monotherapy with 9 months of treatment (9H)
and also, although with less efficacy, using a regime of
isoniazid for 6 months (6H).1,3,4 Rifampin (R) in mono-
therapy for 4 months (4R) also reduces the risk of devel-
oping TB.1,4
Some studies5,6 have shown better cost-effectiveness for
4R than for 9H.
Treatment with 6H has better compliance,7 is cheaper
than 9H, and is recommended as an alternative to 9H4 and
even as a priority.8,9
The aim of this study was to compare the cost-
effectiveness of 4R and 6H.
Patients and methods
In the Central Health Region of Catalonia (Spain), with
more than 1,500,000 inhabitants, LTBI has been treated
with 9H since 1986 and with 4R since 2007.
Study population
The study included all contacts of TB patients with LTBI10
(patients with positive tuberculin test [TT] and absence
of tuberculosis disease). Subjects included were those who
consecutively began treatment with 9H from 1 January
1986 to 31 December 2006 or with 4R from 1 January 2007
to 31 October 2009. Patients with LTBI and HIV infection
and those aged <15 years were excluded.
A self-administered regimen of H (5 mg/kg/24 h, max-
imum 300 mg) plus 50 mg of pyridoxine or R (10 mg/kg/24 h,
maximum 600 mg)1 was used. Exclusion criteria were rea-
sonable suspicion of Mycobacterium tuberculosis (MT)
infection resistant to H or R, intolerance or drug interactions
(according to the treatment used), and active liver disease.
Patients who initiated 9H and completed 180 doses be-
tween 6 and 9 months were considered to have completed
the 6H schedule.4 Adverse effects that appeared before
completion of 180 doses between 6 and 9 months were
classified as corresponding to 6H. If patients did not com-
plete 180 doses between 6 and 9 months, this was consid-
ered as interruption of 6H (due to adverse effects or
voluntarily).Compliance with 4R was defined as the proportion of
patients completing 120 doses in 4e4.5 months.
Patients were informed of possible adverse effects in
order to seekmedical help. Monthly visits were scheduled for
all patients. The medication was provided free at each visit.
In patients treated with 4R, complete blood count and
creatinine, alanine aminotransferase (ALT) and bilirubin in
serum were measured before treatment initiation and after
the first and second months of treatment.
In patients treated with 6H, liver studies were made at
treatment initiation and then every three months in pa-
tients aged <35 years without a history of alcohol con-
sumption or liver disease. In patients with these conditions
or aged >34 years, liver studies were made at treatment
initiation and then every month.
Liver toxicity was defined as ALT 3 times baseline
levels with signs or symptoms of liver disease (nausea,
vomiting, abdominal pain, fever, jaundice) or 5 times
baseline levels after excluding other liver disease.11
Patient data were collected according to the same cri-
teria during the whole study period.
Cost-effectiveness
The cost-effectiveness analysis was carried out from the
perspective of the health care provider, and it was assumed
that the base population was composed of the sum of the
contacts with LTBI treated with 6H plus the contacts with
LTBI treated with 4R and that all the base population were
treated with 4R and, comparatively, with 6H.
We estimated the direct costs (medication, visits, labo-
ratory tests) of 4R and 6H in contacts and the cost of
treating TB in patients in whom it was not avoided. The
total cost was assessed according to the number of cases of
TB avoided (effectiveness).12,13 The time horizon of the
study was five years.
Cost of treatment of LTBI with 4R and with 6H and
cost of TB treatment
The cost of 4R and 6H included the cost of medication (sale
price)14 and of medical visits and laboratory tests.15,16
To estimate the cost of 6H, the weighted mean of the
cost of 6H with three or seven scheduled liver function
studies was calculated. In patients aged <35 years without
a history of alcohol consumption or liver disease, three liver
function studies were assumed (initial and every 3 months
of treatment). In patients with these conditions or aged
>34 years, seven liver function studies (initial and monthly)
were assumed.
The costs of controlling adverse effects were added to
the cost of 4R and 6H and the savings obtained from med-
ication not consumed and scheduled actions not performed
770 J.Ma. Pina et al.were subtracted. The cost of adverse events for 4R inclu-
ded possible hospitalization for 7 days (V 314.25/day)15 and
transfusion or hemodialysis due to thrombocytopenia or
renal failure (V 2871.33).16 In cases of liver toxicity, sero-
logical tests were performed (V 60.81)16 to rule out viral
hepatitis.11 With 6H, the cost of a possible hospital stay for
7 days due to liver toxicity and of possible liver trans-
plantation (V 20,551.25)16 to prevent death from liver
failure was included; for 4R, the cost of liver toxicity was
adjusted according to the frequency of liver damage with
this schedule. If these measures were not necessary, the
hypothetical costs were maintained in the analysis in
accordance with the highest published rate of the disorders
that could cause them.11,17
The cost of TB treatment assumed was V 7398 according
to data from the National Health Service Quality Agency.18
The costs used were those from 2009, with an annual
discount rate of 3% of the cost of treatment until the
appearance of TB in the 5 years following treatment of
LTBI.12,13 It was assumed that the incidence of TB in con-
tacts in whom the treatment of LTBI was not effective
would follow a pattern similar to that observed in the study
by the International Union Against Tuberculosis and Lung
Disease.3
Effectiveness of treatment of LTBI with 4R and 6H
The effectiveness of 4R or 6H achieved in a population with
LTBI was the product of: risk of developing TB of the pop-
ulation with LTBI  efficacy of 4R or 6H  compliance with
4R or 6H.1
Effectiveness was estimated assuming that the contacts
studied were contacts of TB patients with rates of resist-
ance to H of 5.2% and to R of 0.8%, which correspond to the
rates reported by the World Health Organization for the
province of Barcelona.19
The risk of developing TB of all contacts with LTBI
without treatment during the five years following the
diagnosis of LTBI was estimated according to the method of
Vynnycky and Fine.20 In patients aged 15e20 years, the risk
of developing TB in five years was 8.98% for recent infectionTable 1 Characteristics of patients treated with 4R and with 6
4R (n Z 139)
Mean (SD)
Age 32.4 years (11.6)
Induration TT 16.4 mm (5.4)
n (%) (95% CI)
Males 78 (56.2%) (47.5e64.7)
TST convertors 22 (15.8%) (9.4e22.3)
Frequent contacts 71 (51.1%) (42.4e59.7)
Infrequent contacts 46 (33.1% (24.0e31.3)
Immigrants 38 (25.9%) (19.6e35.1)
History of alcohol consumption 68 (48.9%) (40.3e57.6)
Previous liver disease 4 (2.9%) (0.8e7.2)
History of drug addiction 5 (3.6%) (1.2e8.2)
Diabetes mellitus 0
4R: rifampin for 4 months; 6H: isoniazid for 6 months.(<5 years) and 7.57% for recent re-infection (<5 years). For
non-recent infection or re-infection the risk was 0.0150%/
year. In patients aged >20 years, the risk of becoming ill in
five years was 13.8% for recent infection and 8.25% for
recent re-infection. For non-recent infection or re-
infection the risk was 0.0299%/year.20 It was considered
that, in frequent contacts (30 h/week), the incidence of
tuberculosis was 4 times greater than in infrequent con-
tacts (<30 h/week).10,21 The contacts studied were classi-
fied as TT convertors (TT negative in a preceding period of
<2 years)1,10 or TT non-convertors or reactors (no history of
negative TT). Non-convertors were classified as frequent or
infrequent contacts. All convertors were assumed to have
been infected recently. Fifty percent of frequent contacts
were considered as recent infection and 25% as recent re-
infection, while 10% of infrequent contacts were consid-
ered as recent infection and 10% as recent re-infection.22,23
The efficacy adopted for the five years after treatment
was a reduction in morbidity of 90% for 4R24 and 69% for
6H.3
Compliance with 4R or 6H was that found in patients
actually treated with 4R or 6H.
Incremental cost-effectiveness
The incremental cost-effectiveness was estimated using
the formula: [total cost of the strategy with 4R (or
6H)  total cost of the strategy with 6H (or 4R)]/[cases
avoided with 4R (or 6H)  cases avoided with 6H (or 4R)].
When the cost-effectiveness of one treatment was found to
be lowest than the other and more effective, the incre-
mental cost-effectiveness ratio was not calculated and this
treatment was considered dominant.12,13
Sensitivity analysis
A sensitivity analysis of the cost-effectiveness and incre-
mental cost-effectiveness was made for efficacies of 4R of
80%, 69%, 60% and 50%, for the assumption that all patients
studied comprised exclusively infrequent contacts or fre-
quent contacts or convertors and, also for situations inH.
6H (n Z 863)
Mean (SD) Differences in means (95% CI)
31.1 years (11.9) 1.3 (0.8e3.4)
15.7 (5.6) 0.7 (0.3e1.7)
n (% ) (95% CI ) Differences in % (95% CI)
416 (48.2%) (44.8e51.6) 8 (1.4e17.2)
58 (6.7%) (5.0e8.4) 9.1 (2.4e15.8)
343 (39.8%) (36.4e54.1) 11.3 (2.0e20.7)
462 (53.5%) (50.1e56.9) 20.4 (29.4 to 11.5)
38 (4.4%) (3.0e5.8) 21.5 (15.0e30.9)
371 (43.0%) (39.6e46.4) 5.9 (3.4e15.3)
20 (2.2%) (1.3e3.4) 0.7 (2.8e3.9)
12 (1.4%) (0.6e2.2) 2.2 (1.4e5.8)
5 (0.6%) (0.2e1.3) 0.6 (1.5 to 0.3)
4RIF, 6INH, cost-effectiveness 771which compliance with 4R was the same or 5% lower than
compliance with 6H.
Statistical analysis
The mean and standard deviation (SD) were calculated for
age and the TT induration. Proportions with 95% confidence
intervals (CI) and differences of mean and proportions withTable 2 Cost of 4R and 6H.
Price*/unity 4R
N
Rifampin 0.765 12
Isoniazid 300 mg/pyridoxine 50 mg 0.104
Medical visit 34.70 5
Blood sample for analysis þ Blood
count þ creatinine þ liver
function test
33.98 3
Basic cost
Blood sample for analysis þ liver
function test initial and every
3 months (252 patients with no
history of consumption of alcohol
or liver disease and aged <35 years)
23.44
Blood sample for analysis þ liver
function initial and every month
(611 patients with history of
consumption of alcohol or liver
disease or aged >34 years)
23.44
Weighted basic cost
Cost per adverse effects
Visits due to paresthesia 34.70
Pyridoxine 300 mg 0.156
Visits due to hypersensitivity 34.70 1
Antihistaminic 0.566 8
Visits due to digestive intolerance 34.70
Visits þ blood sample for analysis þ
liver function test due to liver response
58.14 3
Hepatitis serology due to toxic liver
response
60.81 2
Visits þ blood sample for analysis-blood
count due to thrombocytopenia
52.74 1
Hospitalization and transfusion or
hemodialysis due to major
hemorrhage or renal failure
2871.33 0.
Hospitalization due to liver toxicity 314.25  7 days 0.
Liver transplant due to liver failure 20551.25 0.
Savings per non-compliance
Rifampin 600 0.765 96
Isoniazid 300 mg/pyridoxine 50 mg 0.104
Visits 34.70 36
Blood sample for analysis þ blood
count þ creatinine þ liver
function test
33.98 21
Blood sample for analysis þ liver
function test:
23.44
Total cost*
4R: rifampin for 4 months; 6H: isoniazid for 6 months; *in euros.95% CI were calculated using previously-defined methods.25
The statistical assessment was made using the Epidat v3.1
program.
This study was approved by the Ethics Committee in
Clinical Research (Fundacio´n Jordi Gol Gorina, Barcelona).
As this was a retrospective study, informed patient
consent was not required. Confidentiality of individual pa-
tient data was respected at all times.6H
umber Cost*/patient Number Cost*/patient
0 91.80
180 18.72
173.50 7 242.90
101.94
367.24
3 70.32
7 164.08
398.32
2 0.08
4 0.0007
0.25 8 0.30
0.03 35 0.02
6 0.20
1.25 362 24.40
0.90 46 3.20
0.38
1% of total 2.87
125% of total 2.74 0.5% of total 9.90
025% of total 5.13 0.1% of total 18.50
0 5.28
13998 1.70
9.00 320 12.30
5.13
220 6.00
361.38 434.92
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Between 1 January 1986 and 31 December 2006, 884
consecutive patients with LTBI who were contacts of
tuberculosis patients were attended. Of these, treatment
with H was not indicated in two patients due to active liver
disease, 13 patients did not accept treatment and six
patients who agreed to participate were finally treated
in other centres. Therefore, 863 patients were finally
included.
Between 1 January 2007 and 31 October 2009, 145 pa-
tients with LTBI were attended and treatment with 4R was
indicated in all except one who had diabetes controlled
with oral hypoglycemics in whom treatment with 9H was
recommended to avoid drug interactions with R.17 Five
patients did not accept treatment. Therefore, 139 patients
accepted treatment with 4R and were included in the
study.
The sum of the patients treated with 6H (863) and the
patients treated with 4R (139) formed the base population
studied, 1002 patients, with a risk of developing TB within 5
years of 6.1% (95% CI: 4.6e7.6).
Table 1 shows the characteristics of the study
population.
Two patients treated with 4R presented adverse medi-
cation effects that did not require treatment suspension:
one patient had digestive intolerance (0.7%; 95% CI:
0.02e3.9) and another had asymptomatic transitory raised
ALT levels (0.7%; 95% CI: 0.02e3.9).
Forty patients treated with 6H had adverse effects that
did not require suspension: digestive intolerance in three
patients (0.3%; 95% CI: 0.07e1.0); peripheral polyneuritis in
two patients (0.2%; 95% CI: 0.03e0.8) and asymptomatic
transitory raised ALT levels in 35 patients (4.1%; 95% CI:
2.7e5.1).
Medication had to be retired due to adverse effects in six
patients treated with 4R, due to thrombocytopenia in one
patient (0.7%; 95% CI: 0.02e3.9); hypersensitivity in three
patients (2.2%; 95% CI: 0.4e6.2) and hepatitis in two pa-
tients (1.4%; 95% CI: 0.2e5.1). Medication was retired in 51
patients treated with 6H: hypersensitivity in five patientsTable 3 Cost-effectiveness and incremental cost-effectiveness
4R in the base population.
Treatment Efficacy Cases of
TB not
avoided
Total cost* Total
effectiveness**
Cost
effe
ratio
6H 69% 29 632303.51 32 1975
4R 90% 11 436842.83 50 873
6H 69% 29 632303.51 32 1975
4R 80% 17 477500.83 44 1085
6H 69% 29 632303.51 32 1975
4R 69% 23 518158.83 38 1363
6H 69% 29 632303.51 32 1975
4R 60% 28 552040.49 33 1672
6H 69% 29 632303.51 32 1975
4R 50% 33 585922.16 28 2092
6H: isoniazid for 6 months; 4R: rifampin for 4 months; TB: tuberculosi
4.6e7.6); compliance with 6H: 75.1% (95% CI 73.1e78.0); compliance(0.6%; 95% CI: 0.2e1.3) and hepatitis in 46 patients (5.3%;
95% CI: 3.7e6.9).
The proportion of patients with asymptomatic transitory
raised ALT levels was greater in patients treatedwith 6H than
in those treatedwith 4R (difference 3.4%; 95% CI: 1.0e5.7) as
was the proportion of cases with hepatitis (difference 3.9%;
95% CI of the difference: 1.0e6.8). Both the hepatic adaptive
response (asymptomatic transitory raised ALT levels11) and
full hepatic toxicity were greater with 6H than with 4R.
Adverse effects remitted after correct therapy or the
withdrawal of treatment. No patients required transfusion,
hemodialysis, hospitalization due to liver toxicity, or liver
transplant.
Voluntary treatment abandonment occurred in 164 pa-
tients (19.0%; 95% CI: 16.3e21.7) treated with 6H and seven
patients (5.0%; 95% CI: 1.0e9.9) treated with 4R. There
were 14% more abandonments with 6H than with 4R (95% CI
of the difference: 9.1e18.9).
The treatment regime was completed in 126 patients
(90.6%; 95% CI: 85.5e95.8) with 4R and 648 patients with 6H
(75.1%; 95% CI: 73.1e78.0). Thus, 15.5% more patients
completed the 4R regimen than the 6H regimen (95% CI of
the difference: 9.5e21.6). Compliance was better with 4R
than with 6H.
Table 2 shows the cost of treatment with 4R and 6H. The
cost of the 4R regimen was 16.9% lower than the cost of the
6H regimen.
The cost-effectiveness ratio was V 8736.86/case of
tuberculosis avoided for 4R and V 19,759.48/case of
tuberculosis avoided for 6H in the base population for an
efficacy of 90% for 4R and an efficacy of 69% for 6H.
Treatment with 4R was dominant.
Table 3 shows the results of the sensitivity analysis for
decreasing efficacies of 4R
Table 4 shows the results of the sensitivity analysis
assuming that the study population was formed exclusively of
infrequent contacts or frequent contacts or convertors, for
decreasingefficaciesof4Rand foracompliancewith4Rbetter
than that with 6H. Table 5 shows the sensitivity analysis for
a compliancewith 4R equal to that of 6H and Table 6 the same
analysis for a compliance with 4R lower than that with 6H.with 4R and 6H. Sensitivity analysis of different efficacies for
* 
ctiveness
Incremental
cost*
Incremental
effectiveness
Incremental
cost*  effectiveness
9.48
6.86 e 18 Dominant
9.48
2.29 e 12 Dominant
9.48
5.76 e 6 Dominant
9.48
8.50 e 1 Dominant
9.48 46381.35 4 11595.34
5.79
s; * in euros; **cases avoided. Risk of developing TB: 6.1% (95% CI
with 4R: 90.6% (95% CI 85.5e95.8).
4RIF, 6INH, cost-effectiveness 773The risk of developing TB was 3.5% (95% CI 1.8e5.2) in
infrequent contacts, 8% (95% CI 5.2e10.7) in frequent
contacts and 12.5% (95% CI 4.6e20.4) in convertors.
Discussion
In the base population studied, the cost-effectiveness ratio
was V 19,759.48/avoided case of tuberculosis if treatment
had been with 6H and V 8736.86/avoided case of tuber-
culosis if treatment had been with 4R. The treatment with
4R was dominant.
The selection criterion for treating with 6H or 4R was
whether patients were treated before or after 1 January
2007.
There were differences between patients treated with
the two schedules. In the treaties with 4R frequentTable 4 Cost-effectiveness and incremental cost-effectiveness
4R and different levels of the risk of developing TB (infrequent
pliance with 4R than with 6H, for all the patients included in the
Risk
levels
Efficacy Cases of
TB not
avoided
Total
cost*
Total
effectiveness**
C
e
r
Infrequent contacts
6H 69% 17 550987.51 18 3
4R 90% 6 402961.16 29 1
6H 69% 17 550987.51 18 3
4R 80% 10 430072.49 25 1
6H 69% 17 550987.51 18 3
4R 69% 13 450395.49 22 2
6H 69% 17 550987.51 18 3
4R 60% 16 470724.49 19 2
6H 69% 17 550987.51 18 3
4R 50% 19 491053.49 16 3
Frequent contacts
6H 69% 39 693290.51 41 1
4R 90% 15 463948.16 65
6H 69% 39 693290.51 41 1
4R 80% 22 511382.50 58
6H 69% 39 693290.51 41 1
4R 69% 30 565593.16 50 1
6H 69% 39 693290.51 41 1
4R 60% 37 606251.16 43 1
6H 69% 39 693290.51 41 1
4R 50% 44 660461.83 36 1
Tuberculin test convertors
6H 69% 60 842369.84 65 1
4R 90% 23 531304.83 102
6H 69% 60 842369.84 65 1
4R 80% 34 592698.49 91
6H 69% 60 842369.84 65 1
4R 69% 47 680790.83 78
6H 69% 60 842369.84 65 1
4R 60% 57 748554.16 68 1
6H 69% 60 842369.84 65 1
4R 50% 68 823093.83 57 1
6H: isoniazid for 6 months; 4R: rifampin for 4 months; TB: tuberculos
The risk of developing TB was 3.5% (95% CI 1.8e5.2) in infrequent conta
4.6e20.4) in convertors. Compliance with 4R: 90.6% and with 6H: 75.contacts and immigrants were more frequent and better
compliance than in the treated with 6H. However the
better compliance with 4R cannot be attributed to the
frequent contacts compliance tends to be better than in
the not frequent,26 since among immigrants tends to be
worse than in autochthonous.27 The better compliance
found for 4R in our study is similar to the results found by
Fresard et al.28 (83% with 4R vs 74% with 6H; pZ 0.02) and
Chan et al.29 (86% with 4R vs 78% with 6H; p Z 0.04). In
addition, Young et al.30 found better compliance with 4R
than with six months of treatment with 9H (90.6% vs. 72.5%;
p Z 0.001).
There were no significant differences between patients
treated with 6H or 4R with respect to alcohol consumption
or liver disease (which both increase liver toxicity due to
H). Therefore, it is not probable that there was anywith 4R and 6H. Sensitivity analysis of different efficacies for
contacts, frequent contacts or convertors) and better com-
base population.
ost* 
ffectiveness
atio
Incremental
cost*
Incremental
effectiveness
Incremental
cost* 
effectiveness
0610.42
3892.21 e 11 Dominant
0610.42
7202.90 e 7 Dominant
0610.42
0472.52 e 4 Dominant
0610.42
4774.97 e 1 Dominant
0610.42 59934.02 2 29967.01
0690.84
6909.52
7137.66 e 24 Dominant
6909.52
8816.94 e 17 Dominant
6909.52
1311.86 e 9 Dominant
6909.52
4098.86 e 2 Dominant
6909.52 32828.68 5 6565.74
8346.16
2959.54
5208.88 e 37 Dominant
2959.54
6513.17 e 26 Dominant
2959.54
8728.09 e 13 Dominant
2959.54
1008.15 e 3 Dominant
2959.54 19276.01 8 2409.50
4440.24
is; * in euros; ** cases avoided.
cts, 8.0% (95% CI 5.2e10.7) in frequent contacts and 12.5% (95% CI
1%.
774 J.Ma. Pina et al.confusion with respect to the difference found in liver
toxicity between 4R and 6H (lower liver toxicity with 4R
than with 6H), confirming the results found by Fresard
et al.28 (liver toxicity: 2% with 4R vs 6.1% with 6H; pZ 0.03)
and Chan et al.29 (liver toxicity: 0% with 4R vs 8.0% with 6H;
p Z 0.001).
The effectiveness of the treatment of LTBI depends on
its efficacy, the risk of becoming ill of the population with
LTBI who are treated, and on treatment compliance.1
The efficacy of 4R is unknown, but estimates by Reich-
man et al.24 suggest that 90% is a reasonable rate. However,
as the reduction in morbidity with rifampin for 3 months
and 6H was considered similar in patients with LTBI and
silicosis,31 the efficacy of 4R would be, at the least, similar
to that assumed for 6H (69%).3
For a 4R compliance (90.6%) better than 6H (75.1%), found
in this study, in the sensitivity analysis, all levels of treatmentTable 5 Cost-effectiveness and incremental cost-effectiveness
4R, different levels of the risk of developing TB (infrequent contac
of 4R and 6H, for all the patients included in the base population
Risk
levels
Efficacy Cases of
TB not
avoided
Total cost* Total
effectiveness**
C
e
r
Infrequent contacts
6H 69% 17 550987.51 18 3
4R 90% 11 436842.83 24 1
6H 69% 17 550987.51 18 3
4R 80% 14 457171.83 21 2
6H 69% 17 550987.51 18 3
4R 69% 17 477500.83 18 2
6H 69% 17 550987.51 18 3
4R 60% 19 491053.48 16 3
6H 69% 17 550987.51 18 3
4R 50% 22 511382.49 13
Frequent contacts
6H 69% 39 693290.51 41 1
4R 90% 26 538487.85 54 9
6H 69% 39 693290.51 41 1
4R 80% 32 579151.85 48 1
6H 69% 39 693290.51 41 1
4R 69% 39 673269.68 41 1
6H 69% 39 693290.51 41 1
4R 60% 44 660461.85 36 1
6H 69% 39 693290.51 41 1
4R 50% 50 701119.85 30 2
Tuberculin test convertors
6H 69% 60 842369.84 65 1
4R 90% 40 633356.51 85 7
6H 69% 60 842369.84 65 1
4R 80% 50 701119.85 75 9
6H 69% 60 842369.84 65 1
4R 69% 60 768883.18 65 1
6H 69% 60 842369.84 65 1
4R 60% 69 829870.16 56 1
6H 69% 60 842369.84 65 1
4R 50% 78 890857.18 47 1
6H: isoniazid for 6 months; 4R: rifampin for 4 months; TB: tuberculos
The risk of developing TB was 3.5% (95% CI 1.8e5.2) in infrequent conta
4.6e20.4) in convertors. Compliance with 4R and with 6H: 75.1%.efficacies for 4Rwere dominant comparedwith 6H, except for
an efficacy of 4R of 50%. The same results were found when
decreasing efficacies of 4R and three risk levels, infrequent
contacts, frequent contacts andconvertors,wereconsidered.
If the rate of compliance with 4R and 6H had been the
same, the dominance of 4R would correspond to an equal
efficacy of 4R and 6H. For an efficacy of 4R lower than that
of 6H, the 6H regimen would be more effective, with an
incremental cost/effectiveness that diminished according
to the increase in the risk of the population becoming ill.
The 6H regimen is dominant for an efficacy of 4R of 50% in
the groups with a higher risk of becoming ill, namely, fre-
quent contacts and convertors.
Finally, if compliance with 6H was better than with 4R,
the 4R regimen is only dominant if its efficacy is superior to
that of 6H. For an efficacy of 4R similar or inferior to that of
6H, the effectiveness of 6H is greater, with an incrementalwith 4R and 6H. Sensitivity analysis of different efficacies for
ts, frequent contacts or convertors) and the same compliance
.
ost* 
ffectiveness
atio
Incremental
cost*
Incremental
effectiveness
Incremental
cost* 
effectiveness
0610.42
8201.78 6 Dominant
0610.42
1770.09 3 Dominant
0610.42
6527.82 0 Dominant
0610.42 59934.02 2 29967.01
0690.84
0610.42 39605.02 5 7921.00
6909.52
972.00 13 Dominant
6909.52
2065.66 7 Dominant
6909.52
6421.21 0 Dominant
6909.52 32828.66 5 6565.73
8346.16
6909.52 11 Dominant
3370.66
2959.54
451.25 20 Dominant
2959.54
348.26 10 Dominant
2959.54
1828.97 0 Dominant
2959.54 12499.68 9 1388.85
4819.11
2959.54 18 Dominant
8954.41
is; * in euros; ** cases avoided.
cts, 8.0% (95% CI 5.2e10.7) in frequent contacts and 12.5% (95% CI
4RIF, 6INH, cost-effectiveness 775cost/effectiveness that diminishes according to the rise in
the risk of developing tuberculosis. The 6H regimen is
dominant for an efficacy of 4R of 50% in frequent contacts
and 60% in convertors.
However, according to our experience and the results of
other reports,28e30 it is highly improbable that compliance
with4Rwouldnotbebetter thanwith6H. Italsoseemsunlikely
that the efficacy of 4R would be inferior to that of 6H, ac-
cording to the results of experimental32 and clinical studies.31
The better compliancewith 4R comparedwith 6H explains
its greater effectiveness. In addition, the lower resistance to
R than to H19 contributes to the greater effectiveness of 4R
compared with 6H and also to the lower cost of treatment
with 4R, which was 16.8% lower than that of 6H.
Cost-effectiveness studies comparing 4R with 9H show
different results. With 9H, in order for the cost-effectivenessTable 6 Cost-effectiveness and incremental cost-effectiveness
4R, different levels of the risk of developing TB (infrequent conta
with 6H than with 4R, for all the patients included in the base p
Risk
levels
Efficacy Cases of
TB not
avoided
Total cost* Total
effectiveness**
C
e
r
Infrequent contacts
6H 69% 17 550987.51 18 3
4R 90% 13 450395.33 22 2
6H 69% 17 550987.51 18 3
4R 80% 15 463948.00 20 2
6H 69% 17 550987.51 18 3
4R 69% 18 484277.00 17 2
6H 69% 17 550987.51 18 3
4R 60% 20 497829.67 15 3
6H 69% 17 550987.51 18 3
4R 50% 22 511382.33 13 3
Frequent contacts
6H 69% 39 693290.51 41 1
4R 90% 26 436221.00 54
6H 69% 39 693290.51 41 1
4R 80% 34 592698.33 46 1
6H 69% 39 693290.51 41 1
4R 69% 41 640132.67 39 1
6H 69% 39 693290.51 41 1
4R 60% 46 674014.33 34 1
6H 69% 39 693290.51 41 1
4R 50% 51 707896.00 29 2
Tuberculin test convertors
6H 69% 60 842369.84 65 1
4R 90% 45 668238.00 80
6H 69% 60 842369.84 65 1
4R 80% 54 728225.00 71 1
6H 69% 60 842369.84 65 1
4R 69% 63 789212.00 62 1
6H 69% 60 842369.84 65 1
4R 60% 71 843422.67 54 1
6H 69% 60 842369.84 65 1
4R 50% 80 904409.67 45 2
6H: isoniazid for 6 months; 4R: rifampin for 4 months; TB: tuberculos
The risk of developing TB was 3.5% (95% CI 1.8e5.2) in infrequent conta
4.6e20.4) in convertors. Compliance with 6H: 75.1% and with 4R: 71.to be favourable to 4R, an efficacy of above 77% would be
necessary, according to one study5 or 70%, according to
another.6 In a study in the population used in the present
study, the cost/effectiveness of 4R and 9Hwas compared and
showed that the cost/effectiveness of 4R was better than
that of 9H for the same risk levels considered in the present
study, always provided that the efficacy of 4R was 75% of
greater.33
This study has some limitations. The diagnosis of LTBI
was based on the absence of TB and the positivity of the TT.
However, the specificity of the TT is inferior to that of
determination in blood of interferon (IFN)-g,34 whose use
might have avoided false positive TT results, with the
consequent reduction in the number of patients diagnosed
with LTBI and the total cost of their treatment with 6H and
4R. However, we believe that this would not havewith 4R and 6H. Sensitivity analysis of different efficacies for
cts, frequent contacts or convertors) and better compliance
opulation.
ost* 
ffectiveness
atio
Incremental
cost*
Incremental
effectiveness
Incremental
cost* 
effectiveness
0610.42
0472.52 4 Dominant
0610.42
3197.40 2 Dominant
0610.42 66710.51 1 66710.51
8486.88
0610.42 53157.84 3 17719.28
3188.64
0610.42 39605.18 5 7921.04
9337.10
6909.52
8078.17 13 Dominant
6909.52
2884.75 5 Dominant
6909.52 53157.84 2 26578.92
6413.66
6909.52 19276.18 7 2753.74
9823.95
6909.52 12 Dominant
4410.21
2959.54
8353.00 25 Dominant
2959.54
9256.70 6 Dominant
2959.54 53157.84 3 17719.28
2729.22
2959.54 11 Dominant
5618.94
2959.54 20 Dominant
0098.00
is; * in euros; ** cases avoided.
cts, 8.0% (95% CI 5.2e10.7) in frequent contacts and 12.5% (95% CI
3%.
776 J.Ma. Pina et al.influenced the comparison of the cost/effectiveness of 6H
and 4R, as this comparison takes into account, in addition
to the effectiveness, the difference between the total cost
of treatment with 6H and with 4R (incremental cost). The
cost of treating all contacts with LTBI with 6H would con-
tinue to be greater that the cost of treating all contacts
with LTBI with 4R, given that the number of false positive
diagnoses of LTBI would be the same for 6H and 4R.
With respect to the representativeness of the sample,
the base population was composed of all contacts of pa-
tients with TB who had LTBI and were attended and treated
consecutively from 1 January 1986 to 31 October 2009.
Therefore, we believe the sample most probably reflects
the population of contacts of TP patients with LTBI.35
Another limitation is that compliance with 6H was not
necessarily similar to compliance with the first 6 months
with 9H. However, in a study that compared compliance
with 6H and H for 12 months (12H), compliance with 6H was
78% (6965 patients studied) and 79% at six months of
treatment with 12H (6919 patients studied).3 Horsburgh
et al.7 found no significant difference between compliance
at six months with 9H and compliance with 6H (57.1%
vs.53.6%).
The efficacy of 6H and 9H, with which the efficacy of 4R
was compared, corresponds to patients with LTBI and
fibrotic lesions and not contacts of patients with TB.3
However, the reduction in morbidity in contacts treated
with 6H was 29% lower than that obtained with 9H,36 which
was not significantly different from the 26% observed in
LTBI patients with fibrotic lesions.3
The detection of H metabolites in urine was not used to
identify non-adherence, as it only provides punctual infor-
mation which varies according to patient pharmacoki-
netics.37 One reason for the monthly scheduled visits was to
study the adverse effects of medication, which required
blood taking for routine analysis or because it was considered
necessary to evaluate adverse effects. It does not seem
reasonable to assume that patients who did not take their
medication would attend control visits and, consequently, it
is unlikely that the estimate of compliance was biased.
In conclusion, the use of 4R instead of 6H is more cost-
effective and results in less liver toxicity.
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